tirzepatide surpass Inside SURPASS-CVOT With Dr. Stephen Nicholls: vs Dulaglutide on Cardiovascular Outcomes Tirzepatide Reduces Time to HbA1c

GLP-1 receptor agonists are approved for conditions such as Type 2 diabetes and certain weight-related indications, not for addiction treatment

57 A similar side-effect profile is seen across the class

For researchers, the choice comes down to which receptor systems and which architecture the protocol requires

Liraglutide (Victoza, Saxenda): Liraglutide, another GLP-1 agonist, offers similar benefits with possibly fewer side effects, making it a suitable option for diabetes management and weight loss

Indicated for external application on the skin and compatible with professional cosmetic protocols for needle-free mesotherapy, superficial cosmetic microneedling and non-invasive transdermal delivery systems using professional equipment